PivotNorth Capital is a venture capital firm in Palo Alto, California. It was founded in 2011 by Tim Connors, formerly of U.S. Venture Partners and Sequoia Capital. PivotNorth raised a 35 million fund when it began in 2011 and sought to raise a second in late 2013.

PivotNorth Capital

Darling Ventures is your partner from Day 1. We lead pre-seed rounds of software businesses, investing throughout North America with first checks up to $750K. Then we get to work on your successful go-to-market. Our firm partners before others muster up their conviction. We make concentrated investments and seek to be the most active and thoughtful investor throughout your Seed phase as your startup finds its footing. We’ve specialized our post-investment support to developing your effective go-to-market strategy. From defining value proposition to the right business model and pitch collateral, we spend the time and deploy our bench of GTM operators to make your market entry a success. While doing so, we value strong integrity, humility and those who hold themselves up to their own highest standards.

Darling Ventures

Early stage investor, co-investments in  North America & Europe. We write small cheques and help with making companies investable for others. Focus: Machine Learning in Health, Industrial. Focus going forward: climate positive startups with real impact (Energy generation, distribution, conservation, mobility, zero waste)

Density Ventures

J. Hunt Holdings is an investment holding company that provides funds for early stage ventures. It is specialized in both domestic and international projects and investments. The company invests between $100,000 and $1,100,000 in five key industry categories, including investment services, portfolio management, accounting, and financial solutions. Mainly focused on the technology and telecommunications sectors, it also invests in the video and sensing, data center management, social media, data security, and other sectors. J. Hunt Holdings is headquartered in Washington, District of Columbia.

J. Hunt Holdings

Citrix Startup Accelerator offers seed funding for passionate entrepreneurs who have great ideas for the development of new technologies and business models around cloud, mobile and collaboration.  The Citrix Startup Accelerator offers:     * Seed funding ($250k)     * An entrepreneur-friendly environment with access to the global Citrix ecosystem.     * An open and interactive accelerator facility in Silicon Valley that offers mentoring  from successful entrepreneurs, Citrix executives, and partners.

Citrix Startup Accelerator

Intel Capital invests in innovative startups targeting cloud and AI infrastructure, edge, 5G, autonomy, cybersecurity, client & gaming, enterprise applications, silicon design and manufacturing, and a wide range of other disruptive technologies. Since 1991, Intel Capital has invested US$12.9 billion in more than 1,582 companies worldwide. Intel Capital has adopted the Diversity Term Sheet Rider.

Intel Capital

UL Ventures is the venture investment and acceleration arm of UL.  UL is a premier global independent safety science company that has championed progress for more than 120 years. Its 14,000 professionals are guided by the UL mission to promote safe working and living environments for all people. UL uses research and standards to continually advance and meet ever-evolving safety needs. We partner with businesses, manufacturers, trade associations and international regulatory authorities to bring solutions to a more complex global supply chain.

UL Ventures

7BC is a venture firm defined by its unique global network. We are a diverse and global set of active strategic individual investors backing our VC funds that support portfolio companies across all stages driving revenue growth, customers, partners, solving problems, fixing technology, raising follow-on investment capital, accessing talent, and buyers resulting in successful high-growth transformational companies. 7BC founders can gain stock in other 7BC portfolio companies for adding value to each other such as fundraising and adding other value, join each others' boards of directors or advisory boards for our startups that opt into this program.

7BC Venture Capital

Morgan Creek Digital is a hedge fund backed by Morgan Creek Capital. Morgan Creek Digital specializes in the fields of digital asset management, financial services, and venture capital. It was founded in 2004 and headquartered in Chapel Hill, North Carolina.

Morgan Creek Digital

Kyndi

Kyndi's Natural Language-powered platform helps organizations find answers in unstructured, text-based data at unparalleled speed.

<div>Kyndi operates an artificial intelligence (AI) platform that can analyze large bodies of unstructured and long-form text. The company mainly serves customers in the pharmaceutical industry, defense, financial services, and manufacturing. In the pharma sector, its platform can be used in various stages from research and development (R&amp;D) to marketing. The AI platform is capable of identifying keywords, custom entities, and phrases to detect trends, find answers using natural language processing, provide data context and location, and can learn industry terminologies. It can be used to search through medical literature and reports to produce insights and develop dashboards to track various information from clinical studies.</div>

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

Kyndi, founded in 2014, developed a Generative AI Answer Engine designed to revolutionize how business users find answers to complex queries. The company's platform leveraged natural language processing, search, and generative AI technologies to provide direct, accurate, and trustworthy information from enterprise content. Kyndi's solution aimed to eliminate hallucinations while offering transparency in results by allowing users to trace back to the sources of answers. The platform integrated embeddings, LLMs, Generative AI, and vector and semantic databases into a fully-integrated end-to-end solution.

Kyndi Introduces New Capabilities to Optimize Knowledge Management and User Experiences with Latest Version of its Generative AI Answer Engine

Kyndi's Generative AI Answer Engine Recognized for Revolutionizing the Way Employees and Customers Find Answers to Queries

Qlik Acquires Kyndi to Enhance AI

Qlik acquires Kyndi's technology to boost AI data analytics

Qlik: "Transformation Only Happens When You Do Something Different and Create Value"

Qlik Acquires Kyndi to Revolutionize AI-Driven Business Insights

Deeptech Company Qlik Buys Kyndi To Offer Unstructured Data Processing Solutions

Using AI to mimic and understand human language

Natural Language Processing Tools

Qlik acquires Kyndi; marks second AI-based acquisition in a month

<div>
 
 Kyndi operates an artificial intelligence (AI) platform that can analyze large bodies of unstructured and long-form text. The company mainly serves customers in the pharmaceutical industry, defense, financial services, and manufacturing. In the pharma sector, its platform can be used in various stages from research and development (R&amp;D) to marketing. The AI platform is capable of identifying keywords, custom entities, and phrases to detect trends, find answers using natural language processing, provide data context and location, and can learn industry terminologies. It can be used to search through medical literature and reports to produce insights and develop dashboards to track various information from clinical studies.
 
</div>

<div>
 
 e-Therapeutics is a UK-based company specializing in drug discovery and development. It leverages computational biology to expedite the drug discovery process, particularly in RNA interference (RNAi) medicines. The company's approach integrates network analysis, machine learning, AI, data mining, and optimization into its proprietary databases and computational tools to identify and develop therapies.&nbsp;
 
 
 The company utilizes two platforms: 1) The HepNet Computational Platform, which is an in-silico (performed via computer simulation) laboratory that allows users to conduct hypotheses, phenotypic screening, and the identification and prioritization of novel therapeutic targets, and 2) the GalOmic RNAi Platform that enables highly specific silencing of gene expression and specializes in the development of RNAi therapies.
 
 
 Further, it has four drug candidates in the pipeline, namely 1) ETX-312 to treat metabolic dysfunction-associated steatohepatitis (MASH), 2) ETX-407 to treat dry age-related macular degeneration (dAMD), 3) ETX-148 to treat pan-haemophilia, and 4) ETX-291 to treat a broad spectrum of cardiometabolic diseases.
 
 
 Key customers and partnerships
 
 
 The company&rsquo;s customers include several pharmaceutical companies to develop therapies using its proprietary platforms. These include partnerships with 
 <a href="https://www.etherapeutics.co.uk/news-and-media/press-releases/e-therapeutics-signs-research-collaboration-agreement-novo-nordisk/">
 Novo Nordisk
 </a>
 (December 2018), 
 <a href="https://www.etherapeutics.co.uk/news-and-media/press-releases/collaboration-galapagos-discover-new-therapeutic-strategies-treatment-idiopathic-pulmonary-fibrosis-and-other-fibrotic-condition/">
 Galapagos
 </a>
 (June 2020), and 
 <a href="https://www.etherapeutics.co.uk/news-and-media/press-releases/immuno-oncology-research-collaboration-iteos-therapeutics/">
 iTeos Therapeutics 
 </a>
 (April 2022). It is also working with another undisclosed top-five pharma company in a specific area of neurodegeneration.&nbsp;
 
 
 Further in May 2018, the company partnered with C4X Discovery to identify new pathophysiological mechanisms in Parkinson&rsquo;s disease.&nbsp;
 
 
 Funding and financials
 
 
 In 2007, the company was listed on the Alternative Investment Market, the London Stock Exchange&rsquo;s public market for small and medium-sized growth companies, under the ticker symbol &ldquo;ETX&rdquo;. Further in 
 <a href="https://sp-edge.com/updates/13462">
 September 2022
 </a>
 , the company raised GBP 13.5 million (USD 15.1 million) from funds managed by institutional investor M&amp;G Investment Management Limited via the subscription of new ordinary shares. The funds were expected to be used for the company's growth initiatives.
 
</div>

eTherapeutics

<div>
 
 HiberCell is a biotechnology company that develops novel therapies focused on oncology. It entered the AI drug discovery space when it acquired AI genomics analysis company Genuity Science (and its subsidiaries in Iceland and Ireland) in August 2021.&nbsp;
 
 
 Genuity Science&rsquo;s solutions include end-to-end therapeutic discovery and development services such as building custom disease datasets, discovering and prioritizing targets, identifying biomarkers, and optimizing clinical trials. Genuity Science leverages its AI-powered platform to manage, process, and analyze genomic data. HiberCell intends to use Genuity Science&rsquo;s AI/ML capabilities to advance its oncology pipeline of five programs, of which one has reached the Phase 2 clinical trial stage.
 
 
 As of March 2024, the company&rsquo;s pipeline included three drug candidates, namely: 1) HC-7366, targeting the general control nonderepressible 2 (GCN2) kinase as part of the integrated stress response (ISR) signaling pathway; 2) HC-5404, aimed at inhibiting the PKR-like endoplasmic reticulum kinase (PERK) involved in the unfolded protein response (UPR) signaling pathway; and 3) odetiglucan, a therapy targeting tumor-immune interactions within the tumor microenvironment​.&nbsp;
 
 
 Key customers and partnerships
 
 
 In December 2023, HiberCell and Merck &amp; Co partnered to conduct a Phase Ib trial to evaluate the combination therapy of belzutifan and HC-7366 for treating clear cell renal cell carcinoma. Further, in January 2021, the company partnered with Biodesix to develop an enzyme-linked immunosorbent assay as a companion diagnostic test.
 
 
 Funding and financials
 
 
 In 
 <a href="https://hibercell.com/news/hibercell-closes-67-4-million-series-b-financing-and-secures-30-million-debt-facility-from-hercules-capital/">
 May 2021
 </a>
 , HiberCell completed a Series B financing round, raising USD 67.4 million, and secured an additional USD 30 million in debt financing from Hercules Capital. The funds were expected to be used for clinical advancement of its novel therapeutic candidates. 
 
</div>

HiberCell

<div>
 
 Arbor Biotechnologies specializes in gene editing to develop novel therapeutics for a variety of indications, starting with liver-related diseases. It operates an AI-powered biodiscovery platform to discover novel CRISPR enzymes, which are sequences of repeating genetic code. To do this, its platform deploys computational search techniques, genome sequencing, gene synthesis, and high-throughput screening. This can eventually be turned into drugs or even applied to agriculture and other industrial uses. In 2018, the company announced the discovery of Cas13d, a new type of gene editing enzyme that helps to alter RNA to treat genetic diseases.&nbsp;
 
 
 As of February 2024, the company had five internal drug discovery programs, of which one was in the IND-enabling stage. It also has multiple collaborative programs under development focused on oncology and various other therapeutic areas.
 
 
 Key customers and partnerships
 
 
 The company has a long-standing partnership with Vertex Pharmaceuticals since
 <a href="https://www.businesswire.com/news/home/20190103005194/en/Vertex-and-Arbor-Biotechnologies-Establish-Collaboration-to-Discover-Novel-Proteins-to-Advance-Discovery-of-Gene-Editing-Therapies">
 January 2019
 </a>
 , which focused on developing gene-editing treatments for cystic fibrosis and four other diseases. The alliance was further extended in 
 <a href="https://www.biospace.com/article/vertex-and-arbor-strike-a-1-2-billion-deal-for-gene-editing-programs/">
 August 2021
 </a>
 and 
 <a href="https://sp-edge.com/updates/15741">
 January 2023
 </a>
 .&nbsp;
 
 
 Other partnerships included a collaboration with 
 <a href="https://www.prnewswire.com/news-releases/arbor-biotechnologies-announces-collaboration-with-ginkgo-bioworks-to-advance-the-discovery-and-development-of-precision-gene-editors-302011991.html">
 Ginkgo Bioworks
 </a>
 (December 2023) to leverage Ginkgo's R&amp;D services to further optimize Arbor's novel precision editors, a non-exclusive licensing agreement with 
 <a href="https://www.globenewswire.com/news-release/2022/02/08/2380680/0/en/EdiGene-and-Arbor-Biotechnologies-Announce-Worldwide-Non-exclusive-License-Agreement-to-Advance-Ex-Vivo-Engineered-Cell-Therapy-Programs.html">
 EdiGene
 </a>
 (February 2022) to leverage Arbor&rsquo;s platform for ex vivo oncology therapies, a strategic research and non-exclusive licensing agreement with 
 <a href="https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-and-arbor-biotechnologies-establish">
 TCR2 Therapeutics
 </a>
 (January 2022) to develop allogeneic TRuC T-cell therapies using Arbor&rsquo;s CRISPR technology, and a license agreement with 
 <a href="https://www.lonza.com/news/2020-12-23-14-00">
 Lonza
 </a>
 (December 2020) to use Arbor&rsquo;s gene-editing technology for Lonza&rsquo;s bioproduction products and services.
 
 
 Funding and financials
 
 
 In its latest Series B funding round in November 2021, which was led by Ally Bridge Group, TCG Crossover, and Temasek, Arbor Biotechnologies raised USD 215 million. The proceeds of the round were earmarked to fuel the company&rsquo;s clinical development pipeline.
 
</div>

Arbor Biotechnologies

Based in the UK, Arctoris provides an automated drug discovery platform, offering fully validated research and development (R&amp;D) processes under an Experiments-as-a-Service model. The company works with biotechnology companies, AI drug discovery companies, pharma and academic institutions enabling these institutions to run experiments in Arctoris’s platform and provides on-demand access to a broad scale of datasets for AI drug discovery companies to train their algorithms.

Arctoris

<div>
 
 Frontier Medicines leverages AI/ML technologies to develop treatments for cancer-causing proteins that are dismissed by traditional pharma companies as undruggable.&nbsp;
 
 
 The company has a proprietary chemoproteomic platform which entails an approach based on the interaction of small-molecule compounds and proteins to screen a large number of targets and combine them with a protein database that contains more than 150,000 novel binding pockets (hotspots). This enables it to access 90% of the human proteome that were not previously targeted due to lack of hotspots. The platform&rsquo;s AI/ML engine incorporates a library of diverse compounds, a hotspot map that serves as the starting point for understanding the druggability of a potential therapeutic target, and lead design and generation.&nbsp;
 
 
 The company focuses on oncology and immunology target and, as of February 2024, it had five wholly-owned therapeutic programs and three AbbVie-partnered programs in its pipeline. All programs were in their discovery stage, except the company&rsquo;s lead candidate, FMC-376 (activated and inactivated forms), focused on treating different cancer types, including non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC), which is in the IND-enabling stage.
 
 
 Key customers and partnerships
 
 
 The company entered a USD 100 million partnership with 
 <a href="https://news.abbvie.com/2020-12-02-AbbVie-and-Frontier-Medicines-Establish-Global-Partnership-to-Discover-and-Develop-Novel-Therapies-and-E3-Degraders-Against-Difficult-to-Drug-Targets">
 AbbVie
 </a>
 In December 2020 to develop small-molecule therapeutics against hard-to-drug protein targets including around 600 E3 ligases (the enzymes that drive the ubiquitination and degradation of proteins.&nbsp;
 
 
 Funding and financials
 
 
 In July 2021, the company raised USD 88.5 million in a 
 <a href="https://sp-edge.com/updates/4347">
 Series B
 </a>
 funding round co-led by Woodline Partners LP and RA Capital Management, with equal participation from Deerfield Management Company. The proceeds were earmarked for advancing the company&rsquo;s drug pipeline and expanding operations in Boston, where its new facility was to complement the company&rsquo;s headquarters in California. 
 
</div>

Frontier Medicines

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies for drug discovery services such as target selection, validation and lead optimization.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to design and run preclinical experiments.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to identify biomarkers (measurable biological signs used to determine disease progression) and predict drug response. 

SaaS (Software-as-a-Service) companies aggregating and analyzing biomedical data with the help of AI to generate insights across the drug development pipeline.

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

Companies leverage GenAI to support drug discovery through accelerated drug designing

Companies offer AI/ML-based SaaS products to accelerate the discovery and development of novel therapeutics

Offers AI/ML-based solutions to accelerate drug discovery and development

Kyndi, founded in 2014, developed a Generative AI Answer Engine designed to revolutionize how business users find answers to complex queries. The company's platform leveraged natural language processing, search, and generative AI technologies to provide direct, accurate, and trustworthy information from enterprise content. Kyndi's solution aimed to eliminate hallucinations while offering transparency in results by allowing users to trace back to the sources of answers. The platform integrated embeddings, LLMs, Generative AI, and vector and semantic databases into a fully-integrated end-to-end solution.
In September 2023, Kyndi released version 6.0 of its Generative AI Answer Engine, introducing new features to address the need for more effective knowledge management and AI transparency. The update included a "Topics" feature that allowed content leaders to curate, validate, and manage knowledge bases in under one hour, and a "Citation" feature that presented end users with content source citations for enhanced AI explainability. Additionally, the platform incorporated end-user feedback mechanisms and query export capabilities to optimize system performance.
In January 2024, Qlik, a leading data integration and analytics company, acquired Kyndi's intellectual property and key technology assets. The acquisition aimed to enhance Qlik's capabilities in leveraging artificial intelligence for business outcomes, particularly in processing unstructured data. Following the acquisition, Kyndi's CEO and leading AI experts joined Qlik to continue advancing the technology within Qlik's ecosystem.

Reduct is a cloud-based video editing and storage platform that enables users to transcribe, organize, and edit video content through text-based interfaces. The platform uses automated transcription technology to convert video and audio files into searchable text transcripts. Users can then highlight, tag, and edit these transcripts to create video clips and reels. Reduct's key differentiator is its ability to edit video by manipulating the corresponding transcript text, allowing for efficient review and compilation of interview footage and other video content. The platform supports various file formats and integrates with video conferencing tools like Zoom for direct import of recordings. Reduct also offers collaborative features, allowing multiple team members to work on projects simultaneously. In addition to its core editing capabilities, Reduct provides unlimited cloud storage for video files, making it a comprehensive solution for video post-production workflows.
Key customers and partnerships
Reduct caters to a range of industries and professionals, including researchers, content creators, marketers, and corporate teams. The platform has developed integrations with popular video editing software like Adobe Premiere Pro, enabling users to export their Reduct projects as editable sequences in these applications. Reduct also supports Final Cut Pro through XML export.

Reduct

MonkeyLearn is an AI-powered text analysis and data visualization platform that enables businesses to extract insights from unstructured textual data. The platform offers both pre-built and custom machine learning models for tasks such as sentiment analysis, keyword extraction, topic detection, and intent classification. MonkeyLearn's no-code interface allows users to clean, label, and visualize customer feedback data without requiring programming skills. The platform can process various types of text data including customer reviews, surveys, social media posts, and support tickets. MonkeyLearn integrates with popular tools like Excel, Google Sheets, Zapier, and Zendesk, allowing users to connect their existing data sources. In 2023, MonkeyLearn launched an all-in-one text analysis and data visualization studio that provides instant insights with greater granularity. The platform offers customizable dashboards and templates for different business scenarios, enabling users to create visualizations tailored to their specific needs.

MonkeyLearn

Keatext is an AI-powered text analytics platform that specializes in interpreting customer feedback. The company's cloud-based solution synthesizes large volumes of unstructured feedback data from multiple channels, including open-survey questions, online reviews, support tickets, chats, and social media posts. Keatext's platform utilizes deep learning and natural language processing to analyze, cluster, correlate, and track customer opinions autonomously, providing actionable insights through a comprehensive dashboard.
The platform is designed to minimize response time and requires no setup, featuring multilingual analysis and context-sensitive, industry-agnostic understanding. It automatically visualizes correlations and trends, offering immediate report-sharing capabilities. Keatext's technology adapts to various industries without requiring algorithm customization, eliminating the need for keywords, lexicons, and semantic dictionaries.
Founded in 2010 by Narjès Boufaden, Keatext initially operated as a professional services provider. In 2015, the company transitioned to a product-based model with the launch of its cloud-based AI-powered text analytics platform. Keatext's solution helps businesses optimize profitability through customer feedback analysis, enabling them to move from assumption-based decision-making to data-driven, research-based strategies. The platform significantly reduces the time required for analyzing customer feedback, with users reporting that tasks that previously took eight hours can now be completed in 10 minutes using Keatext.

Keatext

Aircover is a sale assistant tool that leverages conversational AI and real-time technologies to enhance the efficiency of sales teams. The platform integrates with virtual meetings, providing sales representatives with up-to-date messaging and positioning information. This approach aims to reduce ramp time for new representatives and products, shorten sales cycles, and increase win rates. Aircover's AI-powered system enforces best practices throughout sales meetings, offering real-time answers to representatives and potentially reducing the number of follow-up meetings required per prospect. The tool is designed to serve a wide range of users, from individuals to large enterprises. Aircover also features a relationship management component, allowing users to store notes and track roles within deals. By putting sales enablement on autopilot, the platform seeks to streamline the sales process and improve overall performance.

Aircover

NeuralSpace is an AI SaaS company that specializes in providing advanced text and voice AI technologies in over 100 languages. Founded in 2019, the company focuses on delivering language AI solutions, particularly for Arabic, Indian, and other low-resource languages predominantly spoken in Asia, the Middle East, and Africa. NeuralSpace's platform offers a suite of products including speech-to-text, machine translation, entity recognition, transliteration, data generation, language detection, and text-to-speech conversion. The company's flagship product, VoiceAI, launched in October 2023, provides highly accurate call transcription, translation, and speech analytics for Arabic and Indian languages and dialects, achieving an average accuracy rate of 91%. NeuralSpace utilizes proprietary speech-to-text technology trained on a dataset of 40,000 hours of audio data, which it aims to increase to 100,000 hours. The company's no-code modular toolkit enables enterprises to train and deploy AI models for language processing applications without extensive coding knowledge. NeuralSpace's technology leverages modeling techniques such as transfer learning, multilingual learning, and data augmentation to work effectively with limited text or speech data. The platform can be accessed through a command-line interface, REST APIs, or a no-code GUI, making it versatile for various integration needs.

NeuralSpace

Solutions that use techniques such as named entity recognition, part-of-speech tagging, or summarization to produce insights from unstructured textual documents.

Platforms that summarize conversations, audio, or video files including reactions into text formats.

Tools to identify and analyze the opinions or emotions expressed in survey responses or reviews to produce actionable insights.

Platforms that decipher search queries by analyzing structured and unstructured data based on user intent and behavior.

Solutions that enable real-time conversation through chatbots or automate ticket routing to relevant agents.

Tools that automatically translate text from one language to another.

Tools that detect plagiarism, punctuation errors, or style errors in text.

Companies that use GenAI as a core part of their product offering for natural language processing.

NLP tools such as chatbots are used to cater to each individual

NLP tools are built using AI/ML technologies

Some NLP tools are built using foundation models

NLP tools are provided for other companies to integrate into their workflows

Data Infrastructure & Analytics

INCUMBENTS_PRESENT

<div>
 
 Data integration and analytics firm, Qlik, has announced the procurement of patents and intellectual property from GenAI and natural language processing company, Kyndi.
 Kyndi's AI and machine learning-powered platform facilitates direct, precise results through a natural language search, providing contextual comprehension and explanatory answers.
 Qlik anticipates that integrating Kyndi's solutions into its cloud platform will allow customers to derive decision intelligence enriched with context, by combining structured and unstructured data analysis.
 
</div>

Kyndi

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless